Transcription Factors as Therapeutic Targets in Chronic Kidney Disease
AbstractThe growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation. View Full-Text
Share & Cite This Article
Hishikawa, A.; Hayashi, K.; Itoh, H. Transcription Factors as Therapeutic Targets in Chronic Kidney Disease. Molecules 2018, 23, 1123.
Hishikawa A, Hayashi K, Itoh H. Transcription Factors as Therapeutic Targets in Chronic Kidney Disease. Molecules. 2018; 23(5):1123.Chicago/Turabian Style
Hishikawa, Akihito; Hayashi, Kaori; Itoh, Hiroshi. 2018. "Transcription Factors as Therapeutic Targets in Chronic Kidney Disease." Molecules 23, no. 5: 1123.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.